Display Settings:

Format

Send to:

Choose Destination
    Aliment Pharmacol Ther. 1997 Apr;11(2):273-82.

    Clinical economics review: Helicobacter pylori-associated peptic ulcer disease.

    Source

    Division of Medicine, St James's University Hospital, Leeds, UK.

    Abstract

    The high prevalence and chronic nature of peptic ulcer disease have traditionally resulted in a major economic burden on health care systems. In 1991, for example, peptic ulcer disease was estimated to account for over one-third of all National Health Service expenditure on gastrointestinal diseases. It is now well established that elimination of Helicobacter pylori can lead to a dramatic reduction in gastroduodenal ulcer relapse, with obvious clinical benefits. This review considers the economic implications of the use of H. pylori eradication therapy in peptic ulcer disease.

    PMID:
    9146763
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk